NPPA notifies revised MRPs for 543 brands of anti-cancer drugs, effective 9 November
The National Pharmaceutical Pricing Authority (NPPA) on 28 October released revised maximum retail prices for 543 brands of anti-cancer drugs, which will take effect from 9 November 2026. The sample list shows price cuts of roughly 57% to 90%, such as denosumab falling from about ₹22,031 to ₹5,941 and bevacizumab from about ₹21,768 to ₹5,930 per vial.
Why in news
On 17 October, the NPPA rationalised trade margins on 137 non-scheduled anti-cancer drugs in public interest and asked manufacturers to submit revised prices. The list released now covers submissions received up to 27 October and will keep growing as more companies file.
Prelims pointers
- The NPPA, set up in 1997, functions under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.
- Trade margin is the gap between the price at which a manufacturer sells to the distributor and the MRP paid by the patient. High margins mostly benefit the supply chain, not the patient.
- Trade margin rationalisation for cancer drugs was first tried as a pilot on 42 non-scheduled anti-cancer drugs in 2019.
- The 137 drugs covered include immunotherapy drugs used for more than 20 types of cancer, along with denosumab, pegfilgrastim and bevacizumab.
- Bevacizumab is a monoclonal antibody that blocks VEGF, a protein tumours use to grow new blood vessels.
- Denosumab is a monoclonal antibody against RANKL, used to protect bones in cancers that spread to bone. Pegfilgrastim is a long-acting drug that raises white blood cell counts after chemotherapy.
- Anastrozole is an aromatase inhibitor used in hormone-receptor-positive breast cancer. Its sample MRP fell from about ₹696 to ₹73 for 10 tablets.
Mains angle
Cancer care is one of the biggest drivers of catastrophic health spending in India, and medicines form a large part of that bill. Cutting margins brings prices down without touching manufacturers' selling price. The challenge now is enforcement at retail level, keeping supply steady, and making sure patients actually see the new MRP on the shelf.